Combination chemotherapy using cyclophosphamide, vincristine, methotrexate and 5‐fluorouracil in solid tumors

John J. Costanzi, Charles A. Coltman, Lt Col

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

Results of a combination chemotherapeutic regimen consisting of cyclophosphamide, vincristine, methotrexate and 5‐fluorouracil for disseminated solid tumors in 31 patients are presented. Objective response was noted in 16 of these cases. Particularly responsive were malignant melanoma, pancreatic adenocarcinoma and certain mesenchymal sarcomas. Of those patients achieving a good objective response, the average survival is as follows: malignant melanoma = 9.4 months; pancreatic adenocarcinoma = 20.0+ months; and mesenchymal sarcomas = 13.5 months. Two patients achieved a complete remission after three courses of therapy. One with synovial sarcoma is alive at 27+ months, and the other with melanoma is alive at 11.0+ months. Toxicity was noted in 25 cases with 13 noting moderate toxicity, producing a delay in treatment. Patients' performance status paralleled objective response in most cases. These data reflect some support for the theoretical basis for efficacy of combined drugs in the treatment of disseminated solid tumors.

Original languageEnglish (US)
Pages (from-to)589-596
Number of pages8
JournalCancer
Volume23
Issue number3
DOIs
StatePublished - Mar 1969
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Combination chemotherapy using cyclophosphamide, vincristine, methotrexate and 5‐fluorouracil in solid tumors'. Together they form a unique fingerprint.

Cite this